Publications by authors named "Juan A Bullones Ramirez"
Article Synopsis
- The article reviews the 2023 activity report from the Interventional Cardiology Association of the Spanish Society of Cardiology, highlighting key trends in interventional cardiology practices in Spain.
- A survey involving 119 hospitals revealed a slight decrease in diagnostic studies but an increase in percutaneous coronary interventions (PCI), with a notable rise in the use of drug-coated balloons and techniques for plaque modification.
- The findings indicate a stabilization in coronary interventions while showcasing a growth in complex procedures, particularly for valvular and nonvalvular structural heart diseases, with primary PCI becoming the leading treatment for myocardial infarction.
Article Synopsis
- This article reports on the annual activities of the Interventional Cardiology Association of the Spanish Society of Cardiology for 2022.
- A total of 111 centers participated, revealing a 4.8% increase in diagnostic studies and a significant 22% rise in PCIs on the left main coronary artery, while the overall PCI numbers remained stable.
- Key trends included a preference for the radial approach in 94.9% of cases, increased use of drug-eluting balloons and intracoronary imaging, and a continuous rise in noncoronary procedures, especially those related to heart valve and structural heart issues.
Article Synopsis
- The study compared percutaneous revascularization and conservative treatment for severe lesions in secondary branches of epicardial arteries to evaluate their effectiveness in preventing cardiovascular events.
- After analyzing data from 679 lesions over an average follow-up of 22.2 months, there were no significant differences in outcomes between the two treatment methods, including rates of cardiovascular death and nonfatal myocardial infarction.
- Key factors linked to increased event occurrence included diabetes, history of acute myocardial infarction, and longer lesion length.
Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry.
BMC Cardiovasc Disord
August 2017
Background: Thrombolysis is still used when primary angioplasty is delayed for a long time, but 25%-30% of patients require rescue angioplasty (RA). There are no established recommendations for antithrombotic management in RA. This registry analyzes regimens for antithrombotic management.
View Article and Find Full Text PDFAntagonists of the glycoprotein IIb/IIIa receptor block the binding of fibrinogen and Von Willebrand factor to the platelet receptor. This effect can lead to bleeding and thrombocytopenia. We analyzed the incidence and clinical repercussions of severe thrombocytopenia (< 20 000 /microl) secondary to abciximab treatment in a prospective study of 375 patients (74% men) who underwent percutaneous coronary revascularization and received abciximab at our hospital.
View Article and Find Full Text PDF